BHVN
Biohaven Ltd.
NYSE · Healthcare · Biotechnology · US
$13.62
−1.94%Sep 10, 2026, 11:37 UTC
The U.S. FDA imposed a partial clinical hold on Biohaven's experimental epilepsy drug trials, pausing new patient enrollment after rodent findings.
Aug 26, 2026, 06:56 UTC
Biohaven entered into a licensing agreement with SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, for up to $795 million.
Jul 27, 2026, 11:00 UTC
A federal jury found Avilar Therapeutics and RA Capital willfully and maliciously misappropriated a trade secret developed at Yale, awarding Biohaven and Yale University $4 million.
Jun 29, 2026, 18:04 UTC
Biohaven Ltd. shares fell on Monday after a downgrade by Bank of America Securities.
Source: